Alpha Teknova stock holds as KeyBanc maintains rating

On Wednesday, Alpha Teknova Inc. (NASDAQ:TKNO) received a reaffirmed Sector Weight rating from KeyBanc analysts, following the company’s fourth-quarter financial performance which surpassed expectations. While the stock has experienced a significant 14.93% decline over the past week, InvestingPro data shows the company maintains a strong liquidity position with a current ratio of 4.73. The analysts highlighted that Alpha Teknova’s guidance for the fiscal year 2025 is consistent with current consensus estimates, despite acknowledging potential market challenges.

The company’s management noted that while they entered the year with positive momentum in custom biopharma products, there has been a recent slowdown with some customers delaying orders and others reducing budgets. According to InvestingPro analysis, the company operates with a moderate debt-to-equity ratio of 0.35, providing some financial flexibility during this period of market uncertainty. These issues have been factored into the provided guidance, which anticipates approximately 7% growth in total revenue.

In their assessment, KeyBanc analysts pointed out that the majority of Alpha Teknova’s sales are domestic, with about 95% occurring within the United States. Additionally, all of the company’s manufacturing is carried out domestically, and only a small portion, around 4%, of sales are to academic institutions.

The analysts also observed a positive trend in the broader pharma and biotech funding environment, citing Capital IQ data. According to this data, funding in the sector, including stock offerings and venture capital, reached $91.19 billion in 2024, which is an increase from the $78.78 billion raised in 2023.

In light of the fourth-quarter results and fiscal year 2025 guidance, KeyBanc released a revised model for Alpha Teknova. The updated model reflects the company’s recent financial performance and the expectations set forth for the coming year. Despite the headwinds mentioned, the overall outlook for Alpha Teknova, as suggested by KeyBanc’s maintained Sector Weight rating, appears cautiously optimistic given the context of the current funding landscape. Notably, InvestingPro data reveals the stock has delivered an impressive 111.19% return over the past year. For deeper insights into Alpha Teknova’s financial health and detailed analysis, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.

In other recent news, Alpha Teknova Inc. reported its fourth-quarter and full-year 2024 earnings, showcasing a revenue of $9.3 million, which exceeded the forecast of $8.79 million. The company also posted earnings per share (EPS) of -$0.11, slightly better than the anticipated -$0.12. For the entire year, Alpha Teknova achieved a total revenue of $37.7 million, marking a 3% increase from the previous year, with adjusted revenue growth at 11% when excluding a significant order from 2023. The company’s net loss was reported at $26.7 million, or $0.57 per diluted share, with a notable reduction in free cash outflow from $26.7 million in 2023 to $13.5 million in 2024.

Additionally, Alpha Teknova launched three new products, contributing to its revenue growth and maintained its service levels despite a reduced headcount. The company projects its 2025 revenue to be between $39 million and $42 million, indicating a 7% growth at the midpoint. Analysts from firms like William Blair and KeyBanc Capital Markets have shown interest in the company’s clinical customer pipeline and its potential for future growth. Alpha Teknova also anticipates reducing its free cash outflow to less than $12 million in 2025, aiming for adjusted EBITDA positivity at an annualized revenue of $50-$55 million.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.